CA-PERSONALIS
26.4.2022 14:47:12 CEST | Business Wire | Press release
Evaxion Biotech A/S (Nasdaq: EVAX) and Personalis (Nasdaq: PSNL) announced today that Evaxion will deploy Personalis’ ImmunoID NeXT Platform in a Phase 2b trial to evaluate the efficacy and safety of Evaxion’s personalized cancer immunotherapy EVX-01. The study will combine EVX-01, a neoepitope-targeting immunotherapy based on Evaxion’s proprietary PIONEER® AI technology, with KEYTRUDA® (pembrolizumab) for the treatment of patients with metastatic melanoma.
“We believe we have found the key to efficiently activating the immune system to combat cancer. With our core AI tool called PIONEER, we accurately predict the patient’s most potent neoepitopes, which are the significant mutations of cancer. Then we train the immune system to target those exact mutations, not everything else. That means a higher precision in the therapy than the standard of care treatments out there,” said Lars Wegner, CEO of Evaxion. “We are happy to work with Personalis on this crucial next step when we embark on the Phase 2b study, potentially bringing us closer to fulfilling our aspiration of saving the lives of patients with our AI-powered immunotherapy.”
“Over the past decade, a number of drugs have emerged based on the discovery that the immune system plays a key role in fighting cancer. However, the development of new therapies has been challenged by difficulties in understanding the precise interaction between cancer and the immune system,” said John West, CEO and co-founder of Personalis. “ImmunoID NeXT provides a broad set of insights on tumor and immune biology. Our collaboration with Evaxion may contribute to a better understanding of how combination therapeutics can improve patient outcomes and offer the path to companion diagnostics when relevant biomarkers are identified.”
ImmunoID NeXT® provides a comprehensive, multidimensional view of both a tumor and its immune microenvironment from a single sample. The platform consolidates multiple biomarker assays into one, including advanced analysis of mechanisms of tumor escape, human leukocyte antigen typing and loss of heterozygosity, microsatellite instability, gene expression signatures, T-cell and B-cell receptor repertoires, and immunocellular quantification. ImmunoID NeXT offers a seamless platform for discovery, from translational testing to companion diagnostics.
About Evaxion
Evaxion Biotech A/S is a clinical-stage AI-immunology™ platform company decoding the human immune system to discover and develop novel immunotherapies to treat cancer, bacterial diseases and viral infections. Based on its proprietary and scalable AI-immunology core technology, Evaxion is developing a broad pipeline of novel product candidates, which currently includes three patient-specific cancer immunotherapies.
About Personalis
Personalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform ® is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis' Clinical Laboratory was built with a focus on clinical accuracy, quality, big data, scale, and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website and follow Personalis on LinkedIn and Twitter .
Forward-Looking Statements
All statements in this press release that are not historical are “forward-looking statements” within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the Personalis NeXT Platform, expected benefits of Personalis’ collaboration with Evaxion, Personalis’ business opportunities, leadership, plans or expectations, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis’ filings with the U.S. Securities and Exchange Commission, including Personalis’ most recent reports on Forms 8-K, 10-K and 10-Q, the company’s registration statement on Form S-3 filed on December 30, 2020, and the company’s prospectus supplement filed on January 3, 2022, and include those listed under the caption “Risk Factors.” Personalis disclaims any obligation to update such forward-looking statements.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220426005194/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LTM Joins Athena, a Chainguard-led Industry Coalition to Help Secure Open Source Software in the AI Era24.6.2026 08:30:00 CEST | Press release
LTM, the Business Creativity partner to the world’s largest enterprises, has joined Athena, a new industry coalition led by Chainguard, focused on protecting open source software from the rising threat of AI-driven vulnerabilities. Athena brings together leading organizations across the global software ecosystem to address an urgent challenge. As frontier AI models advance, they are increasingly capable of identifying novel vulnerabilities in open source software at machine speed, often faster than traditional disclosure and patching processes can respond. As AI accelerates both software development and the discovery of vulnerabilities, the window between a flaw being identified and being exploited has narrowed sharply. Athena is designed to close this gap through shared intelligence, coordinated action, and pre-disclosure remediation across the ecosystem. The coalition supports vulnerability management end to end, from discovery and analysis to patching, layered mitigations, and upstr
Over Half of Consumers Will Pay More for Brands That Are Transparent About AI Data Use, New Usercentrics Research Finds24.6.2026 08:30:00 CEST | Press release
52% of consumers globally will pay a 7% premium for AI transparency — rising to 73% in Germany. Almost half have already taken an action with a direct revenue consequence. AI transparency has become a commercial differentiator, and it's reshaping where brand revenue is won — or lost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623804294/en/ Over half (52%) of consumers globally will pay more for brands that are transparent about how they use AI with their data at an average 7% premium. In Germany, that figure rises to 73% of consumers willing to pay a 9% premium, the highest of any market. The finding comes from the second annual State of Digital Trust 2026 Report, commissioned by Usercentrics, a leading data privacy technology company, and conducted by Sapio Research across 11,000 consumers in seven markets. The opportunity for brands that act is matched by the cost of inaction. Almost half (47%) of consumers surveyed
Ilkari Expands European Sovereign Infrastructure Operations With Integration of DC North in Croatia24.6.2026 08:00:00 CEST | Press release
Expansion strengthens Ilkari’s multi-region sovereign infrastructure footprint with EU-based operational capacity, DORA-aligned resilience and sovereign cloud capabilities Croatia's largest carrier-neutral 4 MW data centre, DC North, becomes part of Ilkari's European sovereign infrastructure operations The integration adds operational EU-based data centre capacity, carrier-neutral connectivity and sovereign cloud capabilities across Central and Eastern Europe Expansion enhances Ilkari’s ability to serve regulated, sovereignty-focused and data-intensive enterprise environments across Europe Ilkari, a multinational sovereign infrastructure provider, today announced the integration of DC North in Croatia into its European operations, expanding its sovereign infrastructure footprint across the European Union and strengthening its multi-region platform, which includes existing operations in Iceland and Colombia. This press release features multimedia. View the full release here: https://www
Tigo Energy Predict+ Forecasting Platform Helps YASNO Keep Energy Flowing in Ukraine24.6.2026 06:00:00 CEST | Press release
Advanced energy prediction platform, Predict+, enables Ukrainian utility to better maintain grid service through demand surges, highly variable weather, and infrastructure disruptions. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced that Ukrainian electric utility, YASNO, is the latest enterprise-tier customer to deploy the Tigo Predict+ platform. The AI Energy platform empowers utility operators to adapt to real-world demand challenges as they balance renewable and baseload generation sources. Predict+ currently manages more than 650 GWh and delivers 97.5% forecast accuracy for utility customers. As the leading provider of electricity, gas, and energy-efficiency solutions in Ukraine, YASNO serves more than 2.5 million households in the Kyiv, Dnipropetrovsk, and Donetsk regions, as well as more than 64,000 business customers. YASNO uses the Predict+ platform in ways that go far beyond typical
MSCI Announces the Results of the MSCI 2026 Market Classification Review23.6.2026 23:42:00 CEST | Press release
MSCI released the results of the MSCI 2026 Market Classification Review. Key takeaways from this year's review include: Reclassification of Bulgaria from Standalone to Frontier Market status Assessment of shareholder transparency and coordinated trading concerns in the Indonesian and Turkish equity markets, acknowledging the announced steps undertaken by both markets to address these matters and noting the continued potential for future consultations on the appropriate treatment of these markets if credible progress is not observed Acknowledgement of the removal of floor prices in Bangladesh, with a caution that any reintroduction could prompt a consultation on reclassification from Frontier to Standalone Market status Ongoing monitoring of the implementation of measures aimed at improving the accessibility of the Korean equity market for international institutional investors Reminder on the reclassification of Greece from Emerging to Developed Market status at the May 2027 Index Revie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom